You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2024

Merck And Co Inc Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MERCK AND CO INC, and what generic and branded alternatives to MERCK AND CO INC drugs are available?

MERCK AND CO INC has one approved drug.

Summary for Merck And Co Inc

US Patents:	0
Tradenames:	1
Ingredients:	1
NDAs:	1
Drug Master File Entries:	13

Drugs and US Patents for Merck And Co Inc

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010	AP	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Merck And Co Inc

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010	5,691,336*PED	⤷ Subscribe
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010	7,214,692	⤷ Subscribe
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008	5,512,570	⤷ Subscribe
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008	7,214,692	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for MERCK AND CO INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	115 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	for Oral Suspension	125 mg/Kit	➤ Subscribe	2016-11-23
➤ Subscribe	Capsule	40 mg, 80 mg and 125 mg	➤ Subscribe	2008-11-03
➤ Subscribe	Injection	150 mg/vial	➤ Subscribe	2012-01-25

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.